Premium
Phase 3 trial fails to show benefit of solanezumab in mild Alzheimer's disease
Publication year - 2018
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30330
Subject(s) - medicine , dementia , placebo , disease , oncology , alzheimer's disease , pharmacology , pathology , alternative medicine
A placebo‐controlled trial of the monoclonal antibody solanezumab for treatment of mild dementia associated with Alzheimer's disease has shown no significant effect on cognitive decline. The study failed to confirm secondary results from prior studies that had reported a modest effect.